4basebio (LSE:4BB) has reported a sharp drop in first-half Revenue alongside a big jump in orders and pipeline, leaving investors weighing near-term weakness against signs of growing commercial traction. In its half-year report published on 28 September 2026, the synthetic DNA specialist said revenue for the six months to 30 June fell to £0.3m from £1.2m, while sales orders more than tripled and its qualified pipeline rose to £63m. On the same day the company announced a Supply arrangement linked to TriLink BioTechnologies for a pharmaceutical client's cell therapy programme.

What the Company Does

Based in Cambridge, 4basebio manufactures synthetic DNA using a cell-free, enzymatic process rather than the traditional bacterial plasmid approach. Its main product, opDNA, is designed as starting material for genetic medicines, including gene therapies, genome editing, mRNA production and DNA vaccines. The company holds GMP certification from the UK's medicines regulator and says it has 134 clients. In May 2026 it launched an enzymatic single-stranded DNA platform, and in September it expanded its DNA offering to support personalised cancer vaccines.

Latest Developments

The company has signed a series of commercial agreements in recent months. In May it agreed a clinical supply deal supporting a Phase 2 trial, and in August it entered a strategic collaboration and Marketing agreement with Genezen, a viral vector contract manufacturer. The TriLink announcement, made on 28 September, involves 4basebio supplying clinical-grade opDNA for a multinational pharmaceutical company's cell therapy programme heading into a Phase I trial, with TriLink Manufacturing the mRNA drug substance. Financial terms were not disclosed.

Chief executive Dr Amy Walker described the period as one of strong commercial momentum and said the company enters the second half with greatly enhanced visibility over future revenues. Sales orders reached £1.2m in the half, up 210%, and 28 new programmes had been signed in 2026 at the time of the report.

Financial Picture

The loss for the half widened to £8.9m from £7.8m, with operating cash outflow of £8.4m. Cash stood at £14.1m at 30 June, down from £17.8m at the end of 2025, after the company drew €7m from a Loan Facility provided by 2Invest AG. Normalised gross Margin improved to 72% from 64%. 4basebio attributed the revenue fall to project delays linked to a sector-wide slowdown, US policy changes and tighter biotech funding, and noted that the prior-year figure included a single large clinical contract.

The company now expects full-year 2026 revenue to come in below the £1.7m recorded in 2025, a shift from earlier expectations of strong growth. It expects revenue to grow significantly in the second half and in 2027, with cash outflows reducing, and says its cash runway extends into the second half of 2027. No Dividend is paid.

Sector and index Context

4basebio is one of the more specialised biotechnology names on the FTSE AIM All Share Index. Suppliers to the cell and gene therapy industry have faced a difficult period as funding for smaller biotechs tightened and programmes were delayed or cut, which has weighed on order timing across the sector.

Key Risks

The company remains heavily loss-making and its cash runway is finite, so further funding is likely to be needed if revenue does not scale quickly. Converting the pipeline into revenue depends on customers' clinical programmes progressing, and delays can push income back. Rising loan balances add financial obligations.

What to Watch Next

Investors will watch for evidence that second-half revenue picks up as guided, conversion of the £63m pipeline into firm orders, further pharmaceutical partnerships and progress fitting out the company's new Cambridge facility. Any update on financing ahead of 2027 will also be closely followed.